This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2019 Apr;11(6):461-466.

doi: 10.2217/imt-2019-0021.

Recent clinical trials of immunotherapy in non-small-cell lung cancer

Stavros Gkolfinopoulos¹, Giannis Mountzios²

Affiliations

Affiliations

¹ Medical Oncology Department, BOC Oncology Center, Nicosia 2006, Cyprus.
² 2nd Medical Oncology Department, Henry Dunant Hospital Center, Athens 11526, Greece.

PMID: 30860438
DOI: 10.2217/imt-2019-0021

Recent clinical trials of immunotherapy in non-small-cell lung cancer

Stavros Gkolfinopoulos et al. Immunotherapy. 2019 Apr.

. 2019 Apr;11(6):461-466.

doi: 10.2217/imt-2019-0021.

Authors

Stavros Gkolfinopoulos¹, Giannis Mountzios²

Affiliations

¹ Medical Oncology Department, BOC Oncology Center, Nicosia 2006, Cyprus.
² 2nd Medical Oncology Department, Henry Dunant Hospital Center, Athens 11526, Greece.

PMID: 30860438
DOI: 10.2217/imt-2019-0021

No abstract available

Keywords: atezolizumab; avelumab; checkpoint inhibitors; durvalumab; ipilimumab; nivolumab; non-small-cell lung cancer; pembrolizumab.

PubMed Disclaimer

Similar articles

Role of Immune Checkpoint Inhibitors in Small Cell Lung Cancer.
Cooper MR, Alrajhi AM, Durand CR. Cooper MR, et al. Am J Ther. 2018 May/Jun;25(3):e349-e356. doi: 10.1097/MJT.0000000000000686. Am J Ther. 2018. PMID: 29722737 Review.
Current uses of check inhibitors in the fight against advanced and/or metastatic lung cancer: will immunotherapy overcome chemotherapy?
Cetin B, Bilgetekin İ, Ozet A. Cetin B, et al. Curr Probl Cancer. 2019 Feb;43(1):43-53. doi: 10.1016/j.currproblcancer.2018.07.008. Epub 2018 Aug 4. Curr Probl Cancer. 2019. PMID: 30104030 Review.
[The role of immune checkpoint inhibitors in lung cancer: from clinical trials to clinical practice].
Wang ZM, Song Y. Wang ZM, et al. Zhonghua Jie He He Hu Xi Za Zhi. 2020 Feb 12;43(2):95-99. doi: 10.3760/cma.j.issn.1001-0939.2020.02.006. Zhonghua Jie He He Hu Xi Za Zhi. 2020. PMID: 32062879 Chinese.
Non-small-cell lung cancer: what are the benefits and challenges of treating it with immune checkpoint inhibitors?
Rassy E, Mezquita L, Remon J, Besse B. Rassy E, et al. Immunotherapy. 2019 Sep;11(13):1149-1160. doi: 10.2217/imt-2019-0071. Epub 2019 Jul 30. Immunotherapy. 2019. PMID: 31361172
Immune Checkpoint Inhibitors in Lung Cancer and Melanoma.
Madden K, Kasler MK. Madden K, et al. Semin Oncol Nurs. 2019 Oct;35(5):150932. doi: 10.1016/j.soncn.2019.08.011. Epub 2019 Sep 25. Semin Oncol Nurs. 2019. PMID: 31561846 Review.

See all similar articles

Cited by

A special prognostic indicator: tumor mutation burden combined with immune infiltrates in lung adenocarcinoma with TP53 mutation.
Fu J, Li Y, Li C, Tong Y, Li M, Cang S. Fu J, et al. Transl Cancer Res. 2021 Sep;10(9):3963-3978. doi: 10.21037/tcr-21-565. Transl Cancer Res. 2021. PMID: 35116695 Free PMC article.
Nanomedicine in Non-Small Cell Lung Cancer: From Conventional Treatments to Immunotherapy.
García-Fernández C, Fornaguera C, Borrós S. García-Fernández C, et al. Cancers (Basel). 2020 Jun 18;12(6):1609. doi: 10.3390/cancers12061609. Cancers (Basel). 2020. PMID: 32570729 Free PMC article. Review.
The Role of Pentacyclic Triterpenoids in Non-Small Cell Lung Cancer: The Mechanisms of Action and Therapeutic Potential.
Lee YS, Kwon RJ, Lee HS, Chung JH, Kim YS, Jeong HS, Park SJ, Lee SY, Kim T, Yoon SH. Lee YS, et al. Pharmaceutics. 2024 Dec 26;17(1):22. doi: 10.3390/pharmaceutics17010022. Pharmaceutics. 2024. PMID: 39861671 Free PMC article. Review.
Current Perspectives in Cancer Immunotherapy.
Christofi T, Baritaki S, Falzone L, Libra M, Zaravinos A. Christofi T, et al. Cancers (Basel). 2019 Sep 30;11(10):1472. doi: 10.3390/cancers11101472. Cancers (Basel). 2019. PMID: 31575023 Free PMC article. Review.
The emerging nanomedicine-based technology for non-small cell lung cancer immunotherapy: how far are we from an effective treatment.
Peng L, Xu Q, Yin S, Zhang Y, Wu H, Liu Y, Chen L, Hu Y, Yuan J, Peng K, Lin Q. Peng L, et al. Front Oncol. 2023 Apr 27;13:1153319. doi: 10.3389/fonc.2023.1153319. eCollection 2023. Front Oncol. 2023. PMID: 37182180 Free PMC article. Review.

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
Medical
- MedlinePlus Health Information